Begins commercial shipments of Xenium Cell Segmentation Kit to improve determination of cell boundaries

开始Xenium细胞分割试剂盒的商业装运，以改进细胞边界的确定

Launches first Xenium application-focused panel optimized for immuno-oncology across all tissue types

推出首个针对所有组织类型的免疫肿瘤学优化的Xenium应用程序聚焦面板

PLEASANTON, Calif., March 21, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Xenium multi-modal cell segmentation kit and the launch of a new Xenium gene panel optimized for immuno-oncology applications.

加利福尼亚州普莱森顿，2024年3月21日/PRNewswire/--10x Genomics，Inc.（Nasdaq:TXG），单细胞和空间生物学的领导者，今天宣布其Xenium多模式细胞分割试剂盒的商业可用性，以及针对免疫肿瘤学应用优化的新Xenium基因组的推出。

These new products expand the breadth of the Xenium single cell spatial analysis menu..

这些新产品扩大了Xenium单细胞空间分析菜单的广度。。

'We built Xenium to be the best performing platform for in situ analysis, not only at launch, but for the long term,' said Michael Schnall-Levin, Founding Scientist and Chief Technology Officer at 10x Genomics. 'These new products are a testament to how we listen closely to our customers to build products that are most responsive to their needs.

10x Genomics创始科学家兼首席技术官迈克尔·施纳尔·莱文（MichaelSchnallLevin）说：“我们将Xenium打造成了性能最佳的原位分析平台，不仅在启动时，而且从长远来看。”这些新产品证明了我们如何密切倾听客户的意见，以构建最能满足他们需求的产品。

We have several more launches planned for Xenium this year, as we continue to innovate, enhance and expand our menu of high-performing Xenium assays to help customers answer their specific research questions.'.

随着我们不断创新、增强和扩大高性能Xenium分析的菜单，以帮助客户回答他们的具体研究问题，今年我们计划再推出几款Xenium。”。

Xenium In Situ Cell Segmentation KitThe Xenium In Situ Cell Segmentation Kit improves the determination of cell boundaries by using a stain and algorithmic technique developed and validated through custom-trained machine learning models. Key features:

Xenium原位细胞分割试剂盒Xenium原位细胞分割试剂盒通过使用通过定制训练的机器学习模型开发和验证的染色和算法技术来改进细胞边界的确定。主要特点：

Precise cell segmentation: Use multiple morphological features and a purpose-built algorithm for data-driven, high-confidence transcript-to-cell assignments.

精确的细胞分割：使用多种形态特征和专门构建的算法进行数据驱动的高置信度转录本到细胞的分配。

Diverse stains for comprehensive coverage: Easily capture and visualize tissue architecture in four channels from epithelial and stromal cells, to immune markers, to cell interiors and nuclei.

多种染色剂可实现全面覆盖：从上皮细胞和基质细胞，到免疫标记物，再到细胞内部和细胞核，可以轻松捕获和可视化四个通道中的组织结构。

State-of-the-art, custom-built algorithm: Obtain more accurate cell segmentation with an advanced AI algorithm specifically trained on real-world Xenium cellular and tissue data.

最先进的定制算法：使用专门针对真实Xenium细胞和组织数据训练的高级AI算法，获得更准确的细胞分割。

Immediate access to data: Get interpretation-ready data as soon as the Xenium run is done in open formats that enable seamless compatibility with third-party tools.

立即访问数据：Xenium以开放格式运行后，立即获得可解释的数据，从而实现与第三方工具的无缝兼容性。

Seamless workflow integration and broad tissue and sample compatibility: Cover heterogeneous cell types and tissues in human and mouse samples with a single multi-tissue cocktail, without the need to switch stains for different applications or tissue types. Validated on fresh frozen and FFPE tissues..

无缝工作流程集成以及广泛的组织和样品兼容性：使用单个多组织混合物覆盖人类和小鼠样品中的异质细胞类型和组织，而无需为不同的应用或组织类型切换染色。在新鲜冷冻和FFPE组织上验证。。

'While Xenium launched with a robust nuclear-based segmentation approach, we've built our new solution from the ground up to improve segmentation accuracy,' added Schnall-Levin. 'This solution not only enables researchers to more effectively call cell types, but it also gives more confidence that transcriptomic data is attributed to the correct cell of origin for the most accurate biological interpretation.'.

施纳尔·莱文补充道：“虽然Xenium推出了一种强大的基于核的分割方法，但我们从头开始构建了新的解决方案，以提高分割精度。”这种解决方案不仅使研究人员能够更有效地调用细胞类型，而且还可以更自信地将转录组数据归因于正确的起源细胞，以获得最准确的生物学解释。”。

Quan Nguyen, Group Leader at the University of Queensland, said, 'We have evaluated several computational methods to enhance cell membrane segmentation across various technologies. We found that the experimental data obtained from Xenium membrane staining consistently yields the most accurate segmentation results, leading to improved downstream analysis of cell types and cell-to-cell interactions.

昆士兰大学小组负责人Quan Nguyen说，“我们已经评估了几种计算方法，以增强各种技术的细胞膜分割。我们发现，从Xenium膜染色获得的实验数据始终产生最准确的分割结果，从而改进了细胞类型和细胞间相互作用的下游分析。

We will use this kit in many of our coming Xenium experiments.'.

我们将在未来的许多Xenium实验中使用该试剂盒。”。

Xenium Immuno-Oncology PanelThe Xenium Immuno-Oncology Panel is a comprehensive solution for unraveling the dynamic interplay between tissue biology, tumor biology and immunology. The first application-focused panel on Xenium, this assay is the latest addition to a broad menu of expertly curated and customizable gene panels optimized for specific tissue types and disease states.

Xenium免疫肿瘤学小组Xenium免疫肿瘤学小组是一个全面的解决方案，用于揭示组织生物学，肿瘤生物学和免疫学之间的动态相互作用。作为第一个专注于Xenium的应用小组，该测定法是针对特定组织类型和疾病状态优化的专业策划和可定制基因组的广泛菜单的最新添加。

Key features:.

主要功能：。

Unlock intricate details of the tumor microenvironment: Get extensive detection of diverse immune cell types and states, including their migration, regulation and function, allowing for a deeper understanding of the immune landscape within the tumor microenvironment.

解开肿瘤微环境的复杂细节：广泛检测各种免疫细胞类型和状态，包括它们的迁移，调节和功能，从而可以更深入地了解肿瘤微环境中的免疫景观。

Analyze a variety of cancer types: Examine a broad spectrum of cancer types and tumor biology through the identification of tumor-specific markers, oncogenes, checkpoint proteins and mechanisms of immune evasion, providing insights for the development of targeted therapy strategies.

分析各种癌症类型：通过鉴定肿瘤特异性标志物，癌基因，检查点蛋白和免疫逃避机制来检查广泛的癌症类型和肿瘤生物学，为制定靶向治疗策略提供见解。

Customizable panels: Expand the 380-plex pre-designed panel with up to 100 additional custom genes, enabling a tailored and cost-effective assay.

可定制的面板：使用多达100个额外的定制基因扩展380-plex预先设计的面板，从而实现定制且具有成本效益的检测。

The Xenium Immuno-Oncology Panel is compatible with both fresh frozen and FFPE tissues, ensuring flexibility and reliable performance across various sample types. It is available for pre-order and is expected to ship this month.

Xenium Immuno Oncology面板与新鲜冷冻和FFPE组织兼容，确保了各种样品类型的灵活性和可靠性能。它可以预先订购，预计本月发货。

About 10x Genomics10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology.

约10x Genomics10x Genomics是一家生命科学技术公司，其产品旨在加速对生物学的掌握并促进人类健康。我们的综合解决方案包括用于单细胞和空间生物学的仪器，耗材和软件，可帮助学术和转化研究人员以及生物制药公司以与生物学复杂性相匹配的分辨率和规模了解生物系统。

Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter)..

我们的产品支持肿瘤学、免疫学、神经科学等领域的突破，推动了强有力的发现，改变了世界对健康和疾病的理解。要了解更多信息，请访问10xgenomics.com或通过LinkedIn或X（Twitter）与我们联系。。

Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which fall under the 'safe harbor' provisions of those sections.

前瞻性声明本新闻稿包含《1933年证券法》第27A节（经修订）和《1934年证券交易法》第21E节（经修订）所载《1995年私人证券诉讼改革法》所指的前瞻性声明，这些条款属于这些条款的“安全港”条款。

All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as 'may,' 'might,' 'will,' 'should,' 'expect,' 'plan,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplate,' 'believe,' 'estimate,' 'predict,' 'potential' or 'continue' or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking.

除历史事实陈述外，所有陈述都可能是前瞻性陈述。前瞻性陈述通常可以通过使用前瞻性术语来识别，例如“可能”，“可能”，“意志”，“应该”，“期望”，“计划”，“预期”，“可能”，“打算”，“目标”，“项目”，“沉思”，“相信”，“估计”，“预测”，“潜在”或“继续”或它们的变体或类似术语，但没有这些单词并不意味着陈述不是前瞻性的。

These forward-looking statements include statements regarding 10x Genomics, Inc.'s ('10x Genomics') product launches, performance, configuration, capabilities, adoption and pipeline. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors.

这些前瞻性声明包括有关10x Genomics，Inc.（“10x Genomics”）产品发布、性能、配置、功能、采用和管道的声明。这些陈述基于管理层当前的期望、预测、信念、假设和管理层目前可获得的信息，由于多种因素，实际结果和结果可能与这些陈述存在重大差异。

Other risks and uncertainties that could affect 10x Genomics' financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' and elsewhere in the documents 10x Genomics files with the Securities and Exchange Commission (the 'SEC') from time to .

其他可能影响10x Genomics财务和运营结果并导致实际结果与本新闻稿中前瞻性声明所示结果产生重大差异的风险和不确定性包括标题“风险因素”和“管理层对财务状况和运营结果的讨论和分析”以及10x Genomics不时向证券交易委员会（“SEC”）提交的文件中的其他内容。

Disclosure Information10x Genomics uses filings with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD..

披露信息10x Genomics使用向证券交易委员会、我们的网站（www.10xgenomics.com）、新闻稿、公共电话会议、公共网络广播和我们的社交媒体账户提交的文件，作为披露重大非公开信息的手段，并遵守FD法规规定的披露义务。。

ContactsInvestors: investors@10xgenomics.comMedia: media@10xgenomics.com

联系人投资者：investors@10xgenomics.comMedia时间：media@10xgenomics.com

SOURCE 10x Genomics, Inc

来源10x Genomics，Inc